Steroids in severe pneumonia: A literature review

Minerva Anestesiologica

Volumn 77, Issue 9, 2011, Pages 902-910

  de Pascale, G ^a   Bello, G ^a   Antonelli, M ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Cytokines; Glucocorticoids; Immune response; Pneumonia

Indexed keywords

ADALIMUMAB; AMPICILLIN; CEFTRIAXONE; CORTICOSTEROID; CYTOKINE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; LEVOFLOXACIN; MACROLIDE; METHYLPREDNISOLONE; OSELTAMIVIR; PREDNISOLONE; QUINOLONE DERIVATIVE; RIBAVIRIN; STEROID;

ADULT RESPIRATORY DISTRESS SYNDROME; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG MEGADOSE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG INFECTION; LUNG TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; REVIEW; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; PNEUMONIA; PNEUMONIA, PNEUMOCYSTIS; PNEUMONIA, VIRAL; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STEROIDS;

EID: 80052505485     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Osler W. The Principles and Practice of Medicine. 4th ed. New York: Appleton; 1901. p.108.
2. Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLADR expression as predictors of outcome for patients with community-acquired severe infections. Clin Diagn Lab Immunol 2004;11:161-7.
3. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008;358:716-27.
4. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007;167:1655-63.
5. Wunderink RG. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2009;30:146-53.
6. McGee S, Hirschmann J. Use of corticosteroids in treating infectious diseases. Arch Intern Med 2008;168:1034-46.
7. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24.
8. Schünemann HJ, Jaeschke R, Cook DJ, Bria WF, El-Solh AA, Ernst A et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-14.
9. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired,ventilator-associated, and healthcare- associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
10. Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007;131:1205-15.
11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):27-72.
12. Brown SM, Dean NC. Defining and predicting severe community-acquired pneumonia. Curr Opin Infect Dis 2010;23:158-64.
13. Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008;62:5-34.
14. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
15. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685-93.
16. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999;54:51-5.
17. Igonin AA, Armstrong VW, Shipkova M, Lazareva NB, Kukes VG, Oellerich M. Circulating cytokines as markers of systemic inflammatory response in severe communityacquired pneumonia. Clin Biochem 2004;37:204-9.
18. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002;20:990-5.
19. Fernández-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 2003;10:813-20.
20. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995;108:1303-14.
21. Amsden GW. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21.
22. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:612-20.
23. Calbo E, Alsina M, Rodrìguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 2008;52:2395-402.
24. Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. Am J Respir Crit Care Med 1999;160:1079-100.
25. Wagner HN Jr, Bennett IL Jr, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS.The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 1956;98:197-215.
26. Agustí C, Rañó A, Filella X, González J, Moreno A, Xaubet A et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment:etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488-98.
27. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids on inflammatory response in non immunosuppressed patients with pneumonia: a pilot study. Eur Respir J 1999;14:218-20.
28. Meduri GU, Tolley EA, Chrousos GP, Stentz F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983-91.
29. Rocco PR, Souza AB, Faffe DS, Pássaro CP, Santos FB, Negri EM et al. Effect of corticosteroid on lung parenchyma remodeling at an early phase of acute lung injury. Am J Respir Crit Care Med 2003;168:677-84.
30. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, Patrón JR et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 2008;32:1037-46.
31. Li Y, Cui X, Li X, Solomon SB, Danner RL, Banks SM et al. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: risk and corticosteroids in sepsis. Intensive Care Med 2008;34:568-77.
32. Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006;174:1319-26.
33. Christ-Crain M, Stolz D, Jutla S, Couppis O, Müller C, Bingisser R et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007;176:913-20
34. Gotoh S, Nishimura N, Takahashi O, Shiratsuka H, Horinouchi H, Ono H et al. Adrenal function in patients with community-acquired pneumonia. Eur Respir J 2008;31:1268-73.
35. Salluh JI, Verdeal JC, Mello GW, Araújo LV, Martins GA, de Sousa Santino M et al. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med 2006;32:595-8.
36. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207.
37. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009;48:1429-32.
38. Quispe-Laime AM, Bracco JD, Barberio PA, Campagne CG, Rolfo VE, Umberger R et al. H1N1 influenza A virusassociated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med 2010;36:33-41.
39. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community- acquired pneumonia. Eur Respir J 2007;30:951-6.
40. Kiyokawa K, Kawai S. Efficacy of steroid therapy on adult patients with severe pneumonia. J Infect Chemother. 2010;16:266-71.
41. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, Chan PK et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414-20.
42. Ioanas M, Ferrer M, Cavalcanti M, Ferrer R, Ewig S, Filella X et al. Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. Crit Care Med 2004;32:938-45.
43. McHardy VU, Schonell ME. Ampicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Br Med J 1972;4:569-73.
44. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G et al. Hydrocortisone infusion for severe community- acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005;171:242-8.
45. Annane D, Meduri GU, Marik P. Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future! Eur Respir J 2008;31:1150-2.
46. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993;104:389-92.
47. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55.
48. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of Corticosteroids in Communityacquired Pneumonia - A Randomized Double Blinded Clinical Trial.